Physician profile
Benjamin Collie
NPI 1689029654
$1,557.75
in general payments reported to CMS, 2019-2025
18 companies · $22.44 in 2025
The $22.44 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $41.88 · 2021: $408 · 2022: $352 · 2023: $429 · 2024: $304 · 2025: $22.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $755.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $395.11 | 2021-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $266.10 | 2021-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $155.68 | 2021-2024 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $132.83 | 2021-2023 | Arexvy, Shingrix |
| Dexcom, INC. | $127.86 | 2021-2023 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $78.35 | 2023-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $67.51 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $58.62 | 2023-2024 | |
| Amgen INC. | $54.83 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $43.13 | 2022-2023 | Rexulti |
| Lilly USA, LLC | $31.63 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.90 | 2021-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $26.88 | 2020 | |
| Pfizer INC. | $21.84 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.62 | 2023 | Gvoke Hypopen |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $17.16 | 2023 | Korlym |
| Sunovion Pharmaceuticals INC. | $15.84 | 2022 | |
| Sumitomo Pharma America, INC. | $14.86 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Collie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.